Canaccord Genuity Downgrades MAP Pharmaceuticals (MAPP) to Hold

January 24, 2013 8:43 AM EST
Get Alerts MAPP Hot Sheet
Price: $24.98 --0%

Rating Summary:
    2 Buy, 5 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 18 | Down: 18 | New: 11
Trade MAPP Now!
Join SI Premium – FREE
Canaccord Genuity downgraded MAP Pharmaceuticals (NASDAQ: MAPP) from Buy to Hold with a price target of $25 on of Allergan takeover.

"We’re still surprised by the timing though more may be known when filings come out. At this point we think the deal price is reasonable and for MAPP shareholders it eliminates FDA risk assuming a pre-PDUFA closing (April 15) and in our view for AGN
makes another bidder unlikely."

For an analyst ratings summary and ratings history on MAP Pharmaceuticals click here. For more ratings news on MAP Pharmaceuticals click here.

Shares of MAP Pharmaceuticals closed at $24.71 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities

Canaccord Genuity

Add Your Comment